TASMAR (tolcapone tablets) Patient Assistance Program
Don’t let the high cost of brand COMT inhibitor disrupt your Parkinson’s disease care. We help eligible patients access Tasmar (tolcapone tablets) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Tasmar (tolcapone) is FDA-approved as an adjunct to levodopa/carbidopa for the treatment of Parkinson's disease with motor fluctuations who are not responding satisfactorily to or are not appropriate candidates for other adjunctive therapies. COMT (catechol-O-methyltransferase) inhibitor — prolongs levodopa effect, smooths motor fluctuations, reduces 'off' time.
- Without assistance, brand Tasmar costs commonly run approximately $300–$500 per 30-day supply.
- Through AffordMyPrescriptions, qualifying patients can access Tasmar for a flat $69.95 per month.
- Generic tolcapone available cheaper but rarely used due to boxed hepatotoxicity warning. Other COMT inhibitors typically preferred: entacapone (Comtan — generic, no hepatotoxicity boxed warning; also available in fixed combo with carbidopa/levodopa as Stalevo — generic), opicapone (Ongentys — once-daily, newer, no hepatotoxicity warning). Other Parkinson's medication classes: levodopa/carbidopa (Sinemet — generic, foundational), dopamine agonists (pramipexole, ropinirole, rotigotine patch — generic), MAO-B inhibitors (selegiline, rasagiline — generic; safinamide — Xadago brand), amantadine (generic), anticholinergics (trihexyphenidyl, benztropine — generic). Adenosine A2A antagonist (Nourianz — istradefylline brand). Continuous levodopa infusion (Vyalev — foslevodopa/foscarbidopa).
What Is Tasmar Prescription Assistance Program?
The Tasmar Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Tasmar (used as an adjunct to levodopa/carbidopa in Parkinson’s disease with motor fluctuations) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but the enrollment process involves detailed applications, neurology coordination, supporting documentation, hepatotoxicity monitoring documentation, and ongoing renewal — which can be overwhelming when you are already managing the complexities of advanced Parkinson’s disease.
At AffordMyPrescriptions, our Patient Advocates handle the entire Tasmar PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your neurologist for required documentation (including failure or intolerance of other adjunctive therapies and ongoing liver enzyme monitoring), follow up with the manufacturer’s program until approval, manage your refills, and handle annual re-certification — so you never face a gap in your Tasmar Parkinson’s therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Tasmar enrollment — from the initial application through ongoing refills and annual re-enrollment — so you never face a gap in your Parkinson’s disease treatment.
Pharmacy Price Comparison
- Without assistance, Tasmar costs hundreds of dollars per month at retail pharmacies. Discount cards and pharmacy coupons offer some relief, but they don't come close to what a Patient Assistance Program provides if you qualify. The table below compares typical retail pricing across major pharmacies to what you'd pay with our Tasmar advocacy service:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens (brand) | ~$480/mo | Save substantially |
| CVS Specialty(brand) | ~$500/mo | Save substantially |
| Walmart (brand) | ~$320/mo | Save substantially |
| Costco(brand) | ~$300/mo | Save substantially |
| Generic tolcapone | ~$120/mo | Generic — limited use due to hepatotox |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Tasmar — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Tasmar Prescription Program?
The Tasmar Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — applications that are commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork. Generic entacapone (alternative COMT inhibitor without the hepatotoxicity boxed warning) and opicapone are typically preferred first-line adjuncts.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Tasmar:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $300–$500 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Tasmar assistance.
- You are a U.S. citizen or legal resident
- You Have a Valid Tasmar Prescription From a Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Tasmar:
Tasmar is a peripheral and central COMT inhibitor — blocks degradation of levodopa to 3-O-methyldopa, extending levodopa’s plasma half-life and clinical effect. Tasmar is generally reserved for patients who have failed or cannot tolerate other adjunctive Parkinson’s therapies because of its boxed hepatotoxicity warning. Requires baseline and ongoing liver enzyme monitoring.
How it works:
Parkinson’s disease involves progressive degeneration of dopaminergic neurons in the substantia nigra, causing motor symptoms (tremor, rigidity, bradykinesia, postural instability) and non-motor symptoms. Levodopa/carbidopa remains foundational therapy but its effect fluctuates over time as disease progresses — patients experience ‘on-off’ phenomena and reduced ‘on’ time.
COMT enzyme degrades levodopa. Tolcapone inhibits COMT (both peripheral and central) — extending levodopa exposure, smoothing motor fluctuations, increasing ‘on’ time, and allowing levodopa dose reduction. Tolcapone’s central CNS effect distinguishes it from entacapone (peripheral only) — but also contributes to its hepatotoxicity profile, which has limited its use vs entacapone and opicapone.
Form and use:
Tasmar 100 mg or 200 mg tablets three times daily, taken with carbidopa/levodopa. Levodopa dose typically reduced by 30% at Tasmar initiation. **Mandatory baseline ALT/AST and continued monitoring every 2–4 weeks for first 6 months, then periodically.** Discontinue if ALT/AST exceeds upper
normal threshold per FDA labeling, if jaundice develops, or if clinical hepatitis signs occur. Inform patients of warning signs (fatigue, anorexia, jaundice, dark urine, right upper quadrant pain).
Generic availability:
Generic tolcapone available — limited use due to hepatotoxicity boxed warning. Alternative COMT inhibitors: entacapone (Comtan — generic; also available in fixed combo with carbidopa/levodopa as Stalevo generic; no hepatotoxicity boxed warning — peripherally acting only), opicapone (Ongentys — once-daily, newer, no hepatotoxicity warning). Other PD adjuncts (mostly generic): dopamine agonists (pramipexole, ropinirole, rotigotine patch), MAO-B inhibitors (selegiline, rasagiline, safinamide), amantadine (generic immediate-release and extended-release), anticholinergics (trihexyphenidyl, benztropine), adenosine A2A antagonist (Nourianz/istradefylline — brand), continuous levodopa infusion devices (Vyalev/foslevodopa-foscarbidopa). Deep brain stimulation (DBS) for advanced motor fluctuations.
Warnings:
**Boxed warning: potentially fatal acute fulminant hepatic failure — patients require informed consent regarding this risk, baseline and continued serum ALT/AST monitoring (every 2–4 weeks for first 6 months, then per labeling), and discontinuation if abnormal liver enzymes develop.** Other: orthostatic hypotension, dyskinesia (may worsen — reduce levodopa dose), nausea, diarrhea (sometimes severe), sleep disturbance, hallucinations and other dopaminergic side effects, urine discoloration (orange — benign), drug interactions (CYP2C8 substrate), neuroleptic malignant syndrome (rare), rhabdomyolysis (rare).
FAQ (Frequently Asked Questions)
How Much Does Tasmar Cost Without Insurance?
Brand Tasmar $300–$500 per month. Generic tolcapone $100–$150 per month. Generic entacapone (alternative COMT inhibitor without hepatotoxicity warning) costs $30–$60 per month.
What is the difference between Tasmar and entacapone (Comtan)?
Both are COMT inhibitors that extend levodopa effect. Tolcapone (Tasmar) acts centrally and peripherally — potentially stronger effect but carries the hepatotoxicity boxed warning. Entacapone (Comtan/Stalevo) acts peripherally only — generally preferred first-line because of better safety profile. Tasmar reserved for patients who fail or cannot tolerate entacapone or opicapone.
How serious are the FDA boxed warnings for Tasmar?
Very serious — Tasmar carries a boxed warning for fatal acute fulminant hepatic failure. Patients must provide informed consent and require baseline and serial liver enzyme monitoring (every 2–4 weeks for first 6 months, then periodically). Discontinue at the first sign of liver dysfunction. Because of this risk, Tasmar is typically reserved for patients who have failed or cannot tolerate entacapone or opicapone.
What lab tests are needed while taking Tasmar?
Serum ALT and AST at baseline; every 2–4 weeks for first 6 months; then periodically per FDA labeling. Patients should be educated to report fatigue, loss of appetite, jaundice, dark urine, or right upper quadrant pain immediately.
Can I take Tasmar without an existing diagnosis of Parkinson's disease?
No — Tasmar is indicated only as an adjunct to levodopa/carbidopa in Parkinson’s disease with motor fluctuations. It has no benefit and is not appropriate for other indications
What are the most common side effects of Tasmar beyond liver concerns?
Orthostatic hypotension, dyskinesia (often requires levodopa dose reduction), nausea, diarrhea (sometimes severe and disabling), sleep disturbance, hallucinations or other dopaminergic side effects, orange-colored urine (benign discoloration).
What happens if my Tasmar Patient Assistance Program application is denied?
We help explore generic entacapone (Comtan generic — preferred adjunct, no hepatotoxicity warning), opicapone (Ongentys — once-daily alternative), Stalevo (carbidopa/levodopa/entacapone combo generic), manufacturer copay programs, Parkinson’s Foundation patient assistance, American Parkinson Disease Association resources, and Medicare Part D Extra Help.
Take Control of Your Medication Costs
Advanced Parkinson’s motor-fluctuation management requires careful medication selection. Generic entacapone and opicapone offer COMT inhibition without the hepatotoxicity boxed warning of Tasmar. Our Tasmar advocacy team is ready to verify your eligibility, complete the manufacturer application on your behalf, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help you access Tasmar through a Patient Assistance Program, you are not charged. Call (833) 556-2729 or check your eligibility online today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.